Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03614923 · ClinicalTrials.gov registry record · Phase 2
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Phase 2 study of Chronic Rhinosinusitis, sponsored by AnaptysBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT03614923: Completed Phase 2 study of Chronic Rhinosinusitis, sponsored by AnaptysBio.
NCT03614923 is a Phase 2 study of Chronic Rhinosinusitis that has completed, run by AnaptysBio. The registered enrollment target is 105 participants, below the 164-participant average among 4 other Chronic Rhinosinusitis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03614923, a Phase 2 study of Chronic Rhinosinusitis, has completed, sponsored by AnaptysBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.
Primary Outcome
Nasal polyps were evaluated by nasal endoscopy using centralized imaging data assessments scored by an independent reviewer. Each nostril was scored on a scale from 0 to 4, where a score of 0 means no polyps, and a score of 4 means the presence of polyps causing complete obstruction of the inferior nasal cavity. The bilateral NPS score is the sum of the right and left nostril scores, and hence the total NPS value is between 0 and 8 (worst). A negative change from Baseline indicates improvement
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Etokimab
- DRUG Mometasone Furoate Nasal Spray
Study Locations (20)
California
- Alliance Research Institute - Canoga Park
- DaVinci Research - Roseville
- Sacramento Ear Nose and Throat Surgical and Medical Group Inc. - SacENT - Sacramento
- Allergy & Asthma Medical Group and Research Center - San Diego
Oklahoma
- Allergy Asthma Clinical Research Center - Oklahoma City
- Allergy Asthma and Immunology Center P.C. - Tulsa
- Central States Research, LLC - Tulsa
Florida
- Intermed Medical Research Center - Miami
- Advanced Research Institute, Inc. - New Port Richey
North Carolina
- University of North Carolina Hospitals - Chapel Hill
- Charlotte Eye Ear Nose and Throat Associates - Matthews
Arkansas
- Asthma & Allergy Institute - Little Rock
Colorado
- Colorado Allergy Asthma Centers - Denver
Georgia
- Clinical Research Consultants of Atlanta - Suwanee
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2020-10-26 |
| Phase | Phase 2 |
What the finished NCT03614923 record still lists
NCT03614923 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 164-participant average among 4 other Chronic Rhinosinusitis trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Chronic Rhinosinusitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03614923 names 20 study sites across 13 states, led by California, Oklahoma, Florida.
Frequently Asked Questions
What is clinical trial NCT03614923 about?
NCT03614923 is a clinical study titled "Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)". A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.
What is the current status of trial NCT03614923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2018-11-29. Estimated completion is 2020-10-26.
What conditions does trial NCT03614923 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis.
What interventions are being tested in trial NCT03614923?
The interventions under investigation include: Placebo (BIOLOGICAL), Etokimab (BIOLOGICAL), Mometasone Furoate Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT03614923?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03614923 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
COMPLETED · Phase 3
-
Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations
COMPLETED · Phase 3
-
Point-of-Care Computed Tomography (CT) Chronic Rhinosinusitis Study
COMPLETED · NA
-
An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI